Gritstone Bio Files for Chapter 11 Bankruptcy, Seeks Strategic Alternatives to Preserve Clinical Research
Gritstone Bio, Chapter 11 bankruptcy, strategic alternatives, clinical research, vaccine development, oncology, infectious diseases
Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases
Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration
B. Braun’s Florida IV Fluid Plant Resumes Operations After Minimal Damage from Hurricane Milton
B. Braun, Hurricane Milton, IV Fluids, Florida Facility, Supply Chain
Pfizer Secures EU Approval for TALZENNA in Combination with XTANDI for Metastatic Castration-Resistant Prostate Cancer
TALZENNA, XTANDI, metastatic castration-resistant prostate cancer (mCRPC), PARP inhibitor, European Commission approval, prostate cancer treatment.
Leo Pharma Announces Major Restructuring with Up to 250 Layoffs and Relocations
Leo Pharma, layoffs, relocations, restructuring, biopharma, job cuts
FDA Delays Approval of Zealand Pharma’s Dasiglucagon for Congenital Hyperinsulinism Due to Third-Party Manufacturing Issues
Zealand Pharma, dasiglucagon, congenital hyperinsulinism, FDA, Complete Response Letter, third-party manufacturing issues
Astellas Reduces Universal Cells Workforce in Seattle, Relocates 12 Positions to Japan
Astellas, Universal Cells, layoffs, Seattle, Japan, cell therapy, biotech
Eli Lilly and insitro Collaborate on AI-Driven Metabolic Disease Therapies
Eli Lilly, insitro, AI, metabolic diseases, siRNA, GalNAc, drug discovery, biotechnology, pharmaceutical partnership
Vanqua Bio Advances Experimental Parkinson’s Therapy with VQ-101, Bolsters Leadership Team
Vanqua Bio, VQ-101, Parkinson’s disease, GBA gene mutations, GCase activator, Neurodegenerative diseases, Clinical trials, Lysosomal dysfunction, Alpha-synuclein accumulation
Basecamp Research Secures $60M to Revolutionize AI Drug Discovery with Broad Institute Partnership
AI drug discovery, Basecamp Research, Broad Institute, David R. Liu, Biotechnology, Gene therapy, Artificial intelligence in biology